WHAT IS CLAIMED IS:

1. A solid pharmaceutical composition comprising 4-((R)-2-[5-(2-fluoro-3-methoxy-pheny1)-3-(2-fluoro-6-trifluoromethyl-benzy1)-4-methyl-2,6-dioxo-3,6-dihydro-2H-pyrimidin-1-y1]-1-phenyl-ethylamino)-butyric acid (Compound A) or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable meltable binder, wherein the weight ratio of Compound A or a pharmaceutically acceptable salt thereof to the pharmaceutically acceptable meltable binder is from about 1:1 to about 15:1.

2. The solid pharmaceutical composition of claim 1, wherein the weight ratio of Compound A or a pharmaceutically acceptable salt thereof to the pharmaceutically acceptable meltable binder is from about 3:1 to about 12:1.

3. The solid pharmaceutical composition of claim 1 or 2, wherein the pharmaceutically acceptable meltable binder is selected from the group consisting of polyethylene glycol, hydroxypropylcellulose, d-α tocopheryl polyethylene glycol 1000 succinate and poloxamer.

4. The solid pharmaceutical composition of claim 1 or 2, wherein the pharmaceutically acceptable meltable binder is miscible with 4-((R)-2-[5-(2-fluoro-3-methoxy-pheny1)-3-(2-fluoro-6-trifluoromethyl-benzy1)-4-methy1-2,6-dioxo-3,6-dihydro-2H-pyrimidin-1-yl]-1-phenyl-ethylamino)-butyric acid (Compound A) or a pharmaceutically acceptable salt thereof.

5. The solid pharmaceutical composition of any one of the preceding claims, wherein the pharmaceutically acceptable meltable binder is present in an amount from about 0.5% by weight to about 20% by weight of the solid pharmaceutical composition, preferably from about 2% by weight to about 10% by weight of the solid pharmaceutical composition.

6. The solid pharmaceutical composition of any one of the preceding claims, wherein the solid pharmaceutical composition further comprises a disintegrant;

optionally wherein the disintegrant is selected from the group consisting of cross-linked modified starches, cross-linked polyvinylpyrrolidone, and cross-linked carboxymethyl cellulose, and/or

optionally wherein the disintegrant is present in an amount from about 2% by weight to about 30% by weight of the solid pharmaceutical composition, preferably from about 3% to about 10% by weight of the solid pharmaceutical composition, more preferably from about 4% by weight to about 6% by weight of the solid pharmaceutical composition.

7. The solid pharmaceutical composition of claim 1, wherein the solid pharmaceutical composition further comprises a glidant;

optionally wherein the glidant is colloidal silicon dioxide, and/or

optionally wherein the glidant is present in an amount from about 0.1% by weight to about 5% by weight of the solid pharmaceutical composition, preferably from about 0.2% by weight to about 3% by weight of the solid pharmaceutical composition.

8. The solid pharmaceutical composition of claim 1, wherein the solid pharmaceutical composition further comprises a pH modifying agent;

optionally wherein the pH modifying agent is an alkaline or alkaline earth metal hydroxide, or a weak base with pKa 6, or a polymeric base, a cationic resin, or an alkaline or alkaline earth metal salt, preferably sodium carbonate, and/or

optionally wherein weight weight ratio of Compound A, or salt thereof to the pH modifying agent is from about 1:1 to about 10:1, such as from about 2:1 to about 10:1 or from about 2:1 to about 8:1, or from about 2:1 to about 6:1, or from about 2:1 to about 4:1, or from about 2:1 to about 1:1.

9. The solid pharmaceutical composition of any one of the preceding claims, wherein Compound A or the pharmaceutically acceptable salt thereof is present in an amount from about 40% by weight to about 80% by weight of the solid pharmaceutical composition, preferably in an amount from about 50% by weight to about 70% by weight of the solid pharmaceutical composition;

optionally wherein the solid pharmaceutical composition releases at least about 80% of Compound A or the pharmaceutically acceptable salt thereof in about 60 minutes, measured

using USP apparatus II in 900 mL of sodium phosphate, pH 6.8, at 37 °C and paddle speed of 50 rpm.

10. The solid pharmaceutical composition of claim 1 comprising about 200 mg or comprising about 300 mg of 4-((R)-2-[5-(2-fluoro-3-methoxy-pheny1)-3-(2-fluoro-6-trifluoromethyl-benzy1)-4-methyl-2,6-dioxo-3,6-dihydro-2H-pyrimidin-1-y1]-1-phenyl-ethylamino)-butyric acid (Compound A) or a pharmaceutically acceptable salt thereof; and polyethylene glycol, wherein the polyethylene glycol is present in the solid pharmaceutical composition in an amount from about 2% to about 20%, optionally wherein the polyethylene glycol is polyethylene glycol 3350;

optionally wherein the pharmaceutical composition further comprises a pH modifying agent; optionally wherein the pH modifying agent is an alkaline or alkaline earth metal hydroxide or an alkaline or alkaline earth metal salt, preferably sodium carbonate.

11. The solid pharmaceutical composition of claim 1, the composition comprising:

4-((R)-2-[5-(2-fluoro-3-methoxy-pheny1)-3-(2-fluoro-6-trifluoromethyl-benzy1)-4-methy1-2,6-di oxo-3, 6-dihydro-2H-pyrimidin-l-y1]-1-phenyl-ethylamino)-butyric acid (Compound A) or a pharmaceutically acceptable salt thereof and the pharmaceutically acceptable meltable binder in a solid matrix, such as amorphous solid dispersion;

a pH modifying agent;

a disintegrant; and

a glidant;

wherein the pH modifying agent, the disintegrant, and the glidant are outside the solid dispersion.

12. The solid pharmaceutical composition of claim 11, wherein the pharmaceutically acceptable meltable binder is selected from the group consisting of polyethylene glycol 3350, hydroxypropylcellulose, and poloxamer 188; and/or

wherein the pharmaceutically acceptable meltable binder is present in an amount from about 1% by weight to about 20% by weight of the solid pharmaceutical composition, preferably from about 2% by weight to about 10% by weight of the solid pharmaceutical composition; and/or

wherein the disintegrant is selected from the group consisting of cross-linked modified starches, cross-linked polyvinylpyrrolidone, and cross-linked carboxymethyl cellulose, optionally wherein the disintegrant is present in an amount from about 2% by weight to about 10% by weight of the solid pharmaceutical composition, preferably from about 3% by weight to about 6% by weight of the solid pharmaceutical composition; and/or

wherein the glidant is colloidal silicon dioxide, optionally wherein the glidant is present in an amount from about 0.1% by weight to about 5% by weight of the solid pharmaceutical composition, preferably from about 1% by weight to about 3% by weight of the solid pharmaceutical composition; and/or

wherein the solid pharmaceutical composition further comprises a pH modifying agent, optionally wherein the pH modifying agent is an alkaline or alkaline earth metal hydroxide or an alkaline or alkaline earth metal salt, preferably sodium carbonate and/or optionally wherein weight ratio of the compound A, or salt thereof to the pH modifying agent is from about 1:1 to about 10:1, such as from about 2:1 to about 10:1 or from about 2:1 to about 8:1, or from about 2:1 to about 6:1, or from about 2:1 to about 4:1, or from about 2:1 to about 1:1.

13. The pharmaceutical composition of any preceding claim, wherein the pharmaceutical composition comprises a salt of Compound A;

optionally wherein the salt of Compound A is sodium 4-((R)-2-[5-(2-fluoro-3-methoxy-pheny1)-3-(2-fluoro-6-trifluoromethyl-benzyl)-4-methyl-2,6-dioxo-3,6-dihydro-2H-pyrimidin-l-yl]-1-phenyl-ethylamino)butanoate;

optionally wherein the salt of Compound A is amorphous sodium 4-((R)-2-[5-(2-fluoro-3-methoxy-pheny1)-3-(2-fluoro-6-trifluoromethyl-benzy1)-4-methyl-2,6-di oxo-3,6- dihydro-2H-pyrimidin-1-yl]-1-phenyl-ethylamino)butanoate.

14. A solid pharmaceutical composition according to claim 1, the composition comprising:

(a) from about 55% to about 60% by weight of amorphous sodium 4-((R)-2-[5-(2-fluoro-3-methoxy-pheny1)-3 -(2-fluoro-6-trifluoromethyl-benzy1)-4-methyl-2, 6-dioxo-3,6-dihydro-2H-pyrimidin-l-y1]-1-phenyl-ethylamino)butanoate;

(b) from about 4% to about 6% by weight of a pharmaceutically acceptable hydrophilic meltable polymer;

(c) from about 25% to about 35% by weight of a pH modifying agent;

(d) from about 4% to about 6% by weight of a disintegrant;

(e) from about 0.1% to about 2% by weight of a glidant; and

(f) from about 0.5% to about 1.5% by weight of a lubricant.

15. The solid pharmaceutical composition of claim 14, wherein the pharmaceutically acceptable hydrophilic meltable polymer is polyethylene glycol, preferably polyethylene glycol 3350; and/or

wherein the pH modifying agent is sodium carbonate, preferably sodium carbonate monohydrate; and/or

wherein the disintegrant is crospovidone; and/or

wherein the glidant is colloidal silicon dioxide; and/or

wherein the lubricant is magnesium stearate.

16. Use of the solid pharmaceutical composition of any one of claims 1-15 in the manufacture of a medicament for treating endometriosis, wherein the solid pharmaceutical composition of any one of claims 1-15 is to be administered to a patient in need thereof.

17. Use of the solid pharmaceutical composition of any one of claims 1-15 in the manufacture of a medicament for treating uterine fibroids, wherein the solid pharmaceutical composition of any one of claims 1-15 is to be administered to a patient in need thereof.

18. Use of the solid pharmaceutical composition of any one of claims 1-15 in the manufacture of a medicament for providing partial to substantially full suppression of estradiol in the treatment of a female patient with endometriosis or uterine fibroids, wherein the solid pharmaceutical composition of any one of claims 1-15 is to be administered to the patient;

optionally wherein estradiol levels in the female patient are less than about 50 pg/mL;

optionally wherein estradiol levels in the female patient are less than about 20 pg/mL.

19. Use of the solid pharmaceutical composition of any one of claims 1-15 in the manufacture of a medicament for treating non-dominant adenomyosis or symptomatic adenomyosis, wherein the pharmaceutical composition of claims 1-15 is to be administered to a patient in need thereof;

optionally wherein Compound A is dosed 300 mg twice-a-day or 600 mg once-a-day.

20. Use of a solid pharmaceutical composition in the manufacture of a medicament for treating heavy menstrual bleeding and pelvic pain in a woman with symptomatic adenomyosis, wherein a pharmaceutical composition comprising about 300 mg equivalent of Compound A is to be administered, wherein said composition includes:

(g) about 33.2% by weight of sodium 4-((R)-2-[5-(2-fluoro-3-methoxy-pheny1)-3-(2-fluoro-6-trifluoromethyl-benzy1)-4-methy1-2,6-dioxo-3,6-dihydro-2H-pyrimidin-1-y1]-1 -phenyl-ethylamino)butanoate;

(h) about 16.7% by weight of an alkali metal salt; and

(i) about 51.1% by weight of one or more excipients, wherein the excipients comprises a binder, a water soluble filler, a lubricant, and a film-coating;

optionally said composition comprising:

(a) about 33.2% by weight of sodium 4-((R)-2-[5-(2-fluoro-3-methoxy-pheny1)-3-(2-fluoro-6-trifluoromethyl-benzy1)-4-methy1-2,6-dioxo-3,6-dihydro-2H-pyrimidin-1 -y1]-1 -phenyl-ethylamino)butanoate;

(b) about 2.9% by weight of a binder;

(c) about 16.7% by weight of an alkali metal salt;

(d) about 41.6% by weight of a water soluble filler;

(e) about 1.8% by weight of a lubricant; and

(f) about 3.8% by weight of a film-coating; and/or

optionally wherein the treatment further comprises an add-back therapy selected from a group consisting of estradiol, norethindrone acetate, or combinations thereof, optionally wherein the add-back therapy comprises 1 mg estradiol, 0.5 mg of norethindrone acetate, or combinations thereof and wherein the add-back therapy is to be administered once-a-day, to patients in need thereof.

21. Use of a solid pharmaceutical composition in the manufacture of a medicament for treating heavy menstrual bleeding and pelvic pain in a woman with non-dominant adenomyosis, wherein a pharmaceutical composition comprising about 300 mg equivalent of Compound A is to be administered, wherein said composition includes:

a) about 33.2% by weight of sodium 4-((R)-2-[5-(2-fluoro-3-methoxy-pheny1)-3-(2-fluoro-6-trifluoromethyl-benzy1)-4-methy1-2,6-dioxo-3,6-dihydro-2H-pyrimidin-1-y1]-1 -phenyl-ethylamino)butanoate;
b) about 16.7% by weight of an alkali metal salt; and
c) about 51.1% by weight of one or more excipients, wherein the excipients comprises a binder, a water soluble filler, a lubricant, and a film-coating;

optionally said composition comprising:

a) about 33.2% by weight of sodium 4-((R)-2-[5-(2-fluoro-3-methoxy-pheny1)-3-(2-fluoro-6-trifluoromethyl-benzy1)-4-methy1-2,6-dioxo-3,6-dihydro-21-1-pyrimidin-1-y1]-1 -phenyl-ethylamino)butanoate;
b) about 2.9% by weight of a binder;
c) about 16.7% by weight of an alkali metal salt;
d) about 41.6% by weight of a water soluble filler;
e) about 1.8% by weight of a lubricant; and
f) about 3.8% by weight of a film-coating; and/or

optionally wherein the treatment further comprising an add-back therapy selected from a group consisting of estradiol, norethindrone acetate, or combinations thereof, optionally wherein the add-back therapy comprises 1 mg estradiol, 0.5 mg of norethindrone acetate, or combinations thereof and wherein the add-back therapy is to be administered once-a-day, to patients in need thereof.

22. The use of any of claims 19-21, wherein the non-dominant adenomyosis or symptomatic adenomyosis treatment comprises:

a) Reduction in heavy menstrual bleeding to < 80 ml/mo with a > 50% reduction from baseline in menstrual blood loss (MBL) at Month 6;
b) A clinically meaningful decrease (defined as > 30% reduction from baseline) in pelvic pain at Month 3;

c) Reduction in heavy menstrual bleeding to < 80 ml/mo with a > 50% reduction from baseline in MBL at Month 3;
d) Reduction in heavy menstrual bleeding to < 80 ml/mo with a > 50% reduction from baseline in MBL at Month 12;
e) A clinically meaningful decrease (defined as > 30% reduction) from baseline in pelvic pain at Month 6;
f) MBL volume mean reduction from baseline vs placebo;
g) Suppression of bleeding as defined by amenorrhea +/- spotting;
h) Suppression of menstrual cramps that last throughout the menstrual period;
i)Reduction of pain during intercourse; or
j)Reduction of blood clots that pass during menstrual period.

23. The solid pharmaceutical composition of any one of claims 1 to 15 for use in therapy.